DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
McArthur GA, Chapman PB, Robert C. et al.
Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Lancet Oncol 2014;
15: 323-332
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.